Table 3. Pooled hazard ratios for PFS and OS according to TLG.
| Study selection | N | PFS | N | OS | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Random-effects model | Heterogeneity | Random-effects model | Heterogeneity | |||||||
| Pooled HR (95% CI) | P value | I2 (%) | PH value | Pooled HR (95% CI) | P value | I2 (%) | PH value | |||
| Type of Lymphoma | ||||||||||
| DLBCL | 7 | 2.93(1.89–4.53) | <0.001 | 49.5 | 0.065 | 8 | 3.06(1.52–6.18) | 0.002 | 67.3 | 0.003 |
| PTCL | - | - | - | - | - | - | - | - | - | - |
| ENKTL | 3 | 2.99(1.83–4.89) | <0.001 | 0 | 0.503 | 3 | 2.58(1.33–5.01) | 0.005 | 19 | 0.291 |
| HL | 1 | 6.90(2.59–18.36) | 0.0001 | - | - | 1 | 10.9(3.29–36.23) | 0.0001 | - | - |
| Study Design | ||||||||||
| Retrospective | 10 | 2.97(2.03–4.35) | <0.001 | 35.7 | 0.122 | 11 | 2.28(1.40–3.71) | 0.001 | 50.1 | 0.029 |
| Prospective | 1 | 6.90(2.59–18.36) | 0.0001 | - | - | 1 | 10.9(3.29–36.23) | 0.0001 | - | - |
| Sample size | ||||||||||
| ≥100 | 5 | 4.60(2.83–7.47) | <0.001 | 0 | 0.59 | 4 | 3.54(1.56–8.06) | 0.003 | 62.6 | 0.045 |
| <100 | 6 | 2.73(1.53–4.86) | 0.001 | 48.7 | 0.083 | 9 | 2.07(1.21–3.55) | 0.008 | 54.9 | 0.023 |
| Threshold | ||||||||||
| ≥2.5 | 1 | 6.94(1.41–34.12) | 0.017 | - | - | 1 | 8.63(1.09–68.34) | 0.041 | - | - |
| 41 | 3 | 4.64(2.44–8.85) | <0.001 | 13.9 | 0.313 | 1 | 10.9(3.29–36.23) | 0.0001 | - | - |
| 40 | 3 | 2.16(0.94–4.96) | 0.07 | 60.6 | 0.079 | 3 | 1.90(0.91–3.98) | 0.086 | 43.7 | 0.169 |
| other | 3 | 4.52(2.48–8.21) | <0.001 | 0 | 0.86 | 5 | 3.53(1.98–6.28) | <0.001 | 3.1 | 0.389 |
N: number of studies; HR: hazard ratio; 95% CI: 95% confidence interval; PH: p values of Q test for heterogeneity test; OS: Overall survival; PFS: Progression free survival.